Association Between Beta-Blocker or Statin Drug Use and the Risk of Hemorrhage From Cerebral Cavernous Malformations

Susanna M. Zuurbier; Charlotte R. Hickman; Leon A. Rinkel; Rebecca Berg; Ulrich Sure; Rustam Al-shahi Salman

doi:10.1161/STROKEAHA.121.037009

Association Between Beta-Blocker or Statin Drug Use and the Risk of Hemorrhage From Cerebral Cavernous Malformations

Susanna M. Zuurbier, Charlotte R. Hickman, Leon A. Rinkel, Rebecca Berg, Ulrich Sure, Rustam Al-shahi Salman

Research output: Contribution to journal › Article › peer-review

Original language	English
Journal	Stroke
Early online date	12 Apr 2022
DOIs	https://doi.org/10.1161/STROKEAHA.121.037009
Publication status	E-pub ahead of print - 12 Apr 2022

Access to Document

10.1161/STROKEAHA.121.037009

Association between beta-blockerFinal published version, 9.34 MBLicence: Creative Commons: Attribution (CC-BY)

https://www.ahajournals.org/doi/10.1161/STROKEAHA.121.037009

Cite this

@article{7ba6d71857c14d7080d02351273bebb5,

title = "Association Between Beta-Blocker or Statin Drug Use and the Risk of Hemorrhage From Cerebral Cavernous Malformations",

author = "Zuurbier, {Susanna M.} and Hickman, {Charlotte R.} and Rinkel, {Leon A.} and Rebecca Berg and Ulrich Sure and {Al-shahi Salman}, Rustam",

note = "Funding Information: Amsterdam Brain & Cognition Talent Grant, and the Remmert Adriaan Laan Foundation. The sponsors of this study did not take any part in the study design, collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit this report for publication. The corresponding author had full access to the data in the study and final responsibility for the decision to submit for publication. Funding Information: Dr Zuurbier reports grant from Remmert Adriaan Laan Foundation and the Amsterdam Brain and Cognition, during the conduct of the study. No disclosures relevant to this article for C.R. Hickman, Drs Rinkel, Berg, and Sure. Dr Al-Shahi Salman reports collaboration with the Mario Negri Institue for Pharmacological Research for other services and grants from the Medical Research Council, the Chief Scientist Office of the Scottish Government, and The Stroke Association during the conduct of the study; and consultancy fees from BiovelocITA and Recursion Pharmaceuticals, Inc, paid to the University of Edinburgh, outside the submitted work. This work was supported by the Medical Research Council (clinical training fellowship G84/5176, clinician scientist fellowship G108/613, and senior clinical fellowship G1002605). Publisher Copyright: {\textcopyright} 2022 Lippincott Williams and Wilkins. All rights reserved.",

year = "2022",

month = apr,

day = "12",

doi = "10.1161/STROKEAHA.121.037009",

language = "English",

journal = "Stroke",

issn = "0039-2499",

publisher = "Lippincott Williams & Wilkins",

}

TY - JOUR

T1 - Association Between Beta-Blocker or Statin Drug Use and the Risk of Hemorrhage From Cerebral Cavernous Malformations

AU - Zuurbier, Susanna M.

AU - Hickman, Charlotte R.

AU - Rinkel, Leon A.

AU - Berg, Rebecca

AU - Sure, Ulrich

AU - Al-shahi Salman, Rustam

N1 - Funding Information: Amsterdam Brain & Cognition Talent Grant, and the Remmert Adriaan Laan Foundation. The sponsors of this study did not take any part in the study design, collection, analysis, and interpretation of data; in the writing of the report; and in the decision to submit this report for publication. The corresponding author had full access to the data in the study and final responsibility for the decision to submit for publication. Funding Information: Dr Zuurbier reports grant from Remmert Adriaan Laan Foundation and the Amsterdam Brain and Cognition, during the conduct of the study. No disclosures relevant to this article for C.R. Hickman, Drs Rinkel, Berg, and Sure. Dr Al-Shahi Salman reports collaboration with the Mario Negri Institue for Pharmacological Research for other services and grants from the Medical Research Council, the Chief Scientist Office of the Scottish Government, and The Stroke Association during the conduct of the study; and consultancy fees from BiovelocITA and Recursion Pharmaceuticals, Inc, paid to the University of Edinburgh, outside the submitted work. This work was supported by the Medical Research Council (clinical training fellowship G84/5176, clinician scientist fellowship G108/613, and senior clinical fellowship G1002605). Publisher Copyright: © 2022 Lippincott Williams and Wilkins. All rights reserved.

PY - 2022/4/12

Y1 - 2022/4/12

U2 - 10.1161/STROKEAHA.121.037009

DO - 10.1161/STROKEAHA.121.037009

M3 - Article

SN - 0039-2499

JO - Stroke

JF - Stroke

ER -